The $58 central target is the arithmetic mean of eight current analyst price targets I collected and verified, spanning $33 to $87. The average reflects a split between bullish and more cautious views: six analysts rate the stock Buy, while two (Wells Fargo at $33 and Bank of America at $42) hold Neutral or Equal Weight ratings, with zero Sell ratings. The most recent revisions followed third-quarter results reported on November 10, 2026, when BTIG's Julian Harrison raised his target to $87 from $70, Needham's Serge Belanger raised to $66 from $58, and Jefferies' Amy Li raised to $62 from $55. Other targets include H.C. Wainwright's Andrew Fein at $65, LifeSci Capital's Gaurav Maini at $59, and Raymond James' Ryan Deschner at $53. The wide gap between the $33 low and $87 high underscores how much depends on whether YUTREPIA sustains its growth within a narrower, PAH-only label.
Liquidia closed near $51.40, so reaching $58 requires a rise of about 12.8%, a modest move. The stock sits roughly in the middle of a 52-week range of $22.31 to $93.61, having rebounded sharply from an early-October low after a global settlement with United Therapeutics resolved six lawsuits. The path toward the target hinges on YUTREPIA, the company's inhaled treprostinil therapy for PAH. Third-quarter net product sales rose 31% sequentially to $222.7 million, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $140.5 million, a fifth straight quarterly increase. Management has not yet issued 2027 guidance, saying it will update investors in early January, leaving the near-term narrative driven by prescription and referral trends rather than formal forecasts.
The strongest tailwind is commercial execution. YUTREPIA delivered five consecutive quarters of growth, with a gross margin near 94% and meaningful operating leverage as SG&A (selling, general, and administrative) expense fell to 26% of revenue from 33%. Prescriber breadth is expanding, with about 1,300 prescribers, more first-time prescribers in October than September, and conversion of referrals above 87%. Management estimates a U.S. PAH prostacyclin market of roughly $4 billion, arguing penetration remains small. The litigation resolution also removes a key overhang, and the company has said it can fund the $380.7 million settlement from cash and ongoing sales without raising capital. The L606 program and studies in SSc-RP (systemic sclerosis-associated Raynaud's phenomenon) provide additional, longer-term optionality.
The principal obstacles are structural. The settlement narrows YUTREPIA's approved label to PAH, requiring removal of the PH-ILD (pulmonary hypertension associated with interstitial lung disease) indication, which caps the addressable market versus earlier assumptions and prompted several analysts to slash targets dramatically in October. The company owes roughly $380.7 million in cash through April 2027, and it remains highly concentrated in a single product. Competition from United Therapeutics' Tyvaso franchise and potential future entrants, plus the risk that referral growth decelerates once post-settlement clarity normalizes, could pressure sentiment. Because the stock already reflects substantial expectations, any disappointment in fourth-quarter results or 2027 guidance could trigger valuation compression.
Liquidia's stock has been exceptionally volatile: it traded near $83 in August 2026, fell to a 52-week low of $22.31 on October 1 after an adverse court ruling, then rebounded roughly 115% following the settlement. The $22–$23 zone now marks a durable support area from that capitulation low, while the $93.61 52-week high and the mid-$80s prior plateau represent major resistance overhead. The stock remains below its 200-day moving average, reported near $54.38, a level it would need to reclaim to confirm a longer-term trend change.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ and none specifies a precise date. The most important near-term catalysts are fourth-quarter results and 2027 guidance expected in early January 2027, along with any further analyst revisions as they reassess the PAH-only revenue base. Investors should also track monthly prescription and referral data, the FDA's review of the Prior Approval Supplement removing the PH-ILD label language, enrollment progress in the Re-Spire and AMPLIFY-PAH studies, and any new patent assertions by United Therapeutics against the pipeline.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders spot opportunities, keep an eye on existing positions, and identify changing trends more efficiently than manual scanning alone. For investors watching Liquidia and similar volatile names, pairing these signals with independent research can add a useful technical overlay to fundamental analysis. Explore the signals to see how AI-driven monitoring might complement your own process.
Can Liquidia Corporation stock reach $58? The target is a modest 12.8% above the latest price and represents the average of eight analyst targets, so it is far from a stretch by the stock's own volatile history. The case rests on YUTREPIA's demonstrated commercial momentum, improving operating leverage, and the removal of a major legal overhang. The counterargument rests on the narrowed PAH-only label, the cash settlement burden, and a valuation that already prices in continued strong growth. With a range spanning $33 to $87, the Street itself is divided on how much of the pre-settlement opportunity remains. The upcoming fourth-quarter report and 2027 outlook will likely determine whether the stock can close that 12.8% gap.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with UNCY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then UNCY could also see price increases.
| Ticker / NAME | Correlation To LQDA | 1D Price Change % | ||
|---|---|---|---|---|
| LQDA | 100% | +0.41% | ||
| UNCY - LQDA | 34% Loosely correlated | -1.12% | ||
| GOSS - LQDA | 34% Loosely correlated | -1.75% | ||
| VIR - LQDA | 32% Poorly correlated | -3.06% | ||
| KROS - LQDA | 32% Poorly correlated | -5.08% | ||
| MNKD - LQDA | 32% Poorly correlated | -2.95% | ||
More | ||||
| Ticker / NAME | Correlation To LQDA | 1D Price Change % |
|---|---|---|
| LQDA | 100% | +0.41% |
| Pharmaceuticals: Generic industry (81 stocks) | -7% Poorly correlated | -3.26% |
| Pharmaceuticals industry (151 stocks) | -8% Poorly correlated | -3.00% |